奥希替尼和吉非替尼/厄洛替尼一线治疗EGFR突变阳性非小细胞肺癌的成本-效果分析
王皓,曾晨欣,李俐,葛卫红
Cost-Effectiveness Analysis of Osimertinib and Gefitinib/Erlotinib as the First-line Therapy for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
Hao WANG,Chenxin ZENG,Li LI,Weihong GE
医药导报
.
2020, (12): 1689
-1696
.
DOI: 10.3870/j.issn.1004-0781.2020.12.018